Paul L Crispen
Overview
Explore the profile of Paul L Crispen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2026
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen T, Ordulu Z, Shrestha S, Patel U, Crispen P, Brown L, et al.
Front Endocrinol (Lausanne)
. 2024 Jun;
15:1386285.
PMID: 38911036
Background: Paragangliomas (PGL) are rare neuroendocrine tumors derived from the autonomic nervous system paraganglia. Urinary bladder paragangliomas (UBPGL) originate from the sympathetic neurons of the urinary bladder wall and represent...
2.
Massari M, OMalley P, Benidir T, Su L, Gao H, Crispen P
Urol Oncol
. 2024 May;
42(9):289.e7-289.e12.
PMID: 38802293
Purpose: To evaluate the efficacy of intravesical (IVe) Bacillus Calmette-Guerin (BCG) to treat non-muscle invasive bladder cancer (NMIBC) recurrences in patients who have previously undergone nephroureterectomy for upper tract urothelial...
3.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
4.
5.
Donelan W, Crispen P, Kusmartsev S
Methods Mol Biol
. 2023 Jul;
2684:167-175.
PMID: 37410234
Hyaluronan is a major component of the extracellular matrix in both normal and tumor tissue. Many solid cancers, including bladder cancer, are characterized by deregulated hyaluronan metabolism. It is postulated...
6.
Miyagi H, Kwenda E, Ramnaraign B, Chatzkel J, Brisbane W, OMalley P, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612164
Muscle-invasive bladder cancer is a life-threatening disease best managed with multimodal therapy. Neoadjuvant chemotherapy prior to cystectomy significantly improves survival with the greatest benefit noted in patients with a complete...
7.
8.
Dominguez-Gutierrez P, Kwenda E, Donelan W, Miranda M, Doty A, OMalley P, et al.
J Immunol
. 2022 May;
208(12):2829-2836.
PMID: 35589125
Expression of the transmembrane protein PD-L1 is frequently upregulated in cancer. Because PD-L1-expressing cells can induce apoptosis or anergy of T lymphocytes through binding to the PD1 receptor, the PD-L1-mediated...
9.
Kusmartsev S, Kwenda E, Dominguez-Gutierrez P, Crispen P, OMalley P
J Kidney Cancer VHL
. 2022 May;
9(2):1-6.
PMID: 35528727
Renal cell carcinoma (RCC) patients frequently have increased number of immunosuppressive myeloid cells in circulation. High number of myeloid-derived suppressor cells (MDSCs) in the blood are associated with immune suppression...
10.
Mitra A, Narayan V, Mokkapati S, Miest T, Boorjian S, Alemozaffar M, et al.
Eur Urol
. 2021 Dec;
81(3):223-228.
PMID: 34933753
A recent phase 3 trial of intravesical nadofaragene firadenovec reported a promising complete response rate for patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. This study examined the ability of antiadenovirus...